Gene
TUBB3
TUBB3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (19), Actionable biomarkers (1), Target-disease associations (411), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention TUBB3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Publication mentions | Share of that year |
|---|---|---|
| 2023 | 2 of 11,460 | 0.02% |
| 2022 | 3 of 13,598 | 0.02% |
| 2021 | 6 of 15,045 | 0.04% |
| 2020 | 5 of 14,459 | 0.03% |
| 2019 | 9 of 12,159 | 0.07% |
| 2018 | 5 of 11,854 | 0.04% |
| 2017 | 6 of 11,595 | 0.05% |
| 2016 | 2 of 10,983 | 0.02% |
| 2015 | 4 of 11,395 | 0.04% |
| 2014 | 6 of 10,367 | 0.06% |
Showing 10 of 34 years.
Assay-provider ledger (19)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Daiichi Sankyo | Pharma or other | No clinical or analytical validation recorded for this pair | 1 | April 03, 2014 |
| Eisai | Pharma or other | No clinical or analytical validation recorded for this pair | 1 | April 03, 2014 |
| San Bio, Inc. | Pharma or other | No clinical or analytical validation recorded for this pair | 1 | April 03, 2014 |
| CalBiochem | Reagent supplier | Clinical validationAnalytical validation | 1 | December 01, 2013 |
| Life Technologies | Reagent supplier | Clinical validationAnalytical validation | 2 | December 01, 2013 +1 undated |
Showing 5 of 19 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| TUBB3 overexpression | (nab)-paclitaxel | responsive | No disease recorded | Cancer Genome Interpreter |
Target-disease associations (411)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AL amyloidosis | cardiovascular disease | Clinical precedence |
| Abnormal cerebral morphology | phenotype | Variant curation (ClinVar / EVA) |
| Abnormality of skin pigmentation | phenotype | GWAS credible sets |
| Agnathia - holoprosencephaly - situs inversus | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Clinical precedence |
Showing 5 of 411 associations.
Vendor sourcing (25)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). It is not observed in the gnomAD v2.1.1 da... | View ClinVar record SCV002011953.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.756G>C (p.K252N) alteration is located in exon 4 (coding exon 4) of the TUBB3 gene. This alteration results from a G to C substitution at nucleotide po... | View ClinVar record SCV003560923.2 |
| Baylor College of Medicine | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | PS2, PS3, PS4, PM2, PM3 | View ClinVar record SCV006555427.1 |
| Centre Hospitalier Universitaire de Nantes | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV004101171.1 |
| DASA (Brazil) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.136C>T;p.(Arg46Trp) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 438582; PM... | View ClinVar record SCV002073749.2 |
Showing 5 of 25 sourcing records.
Trial-cited literature (63)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. | Cancers | 2023 | 70 |
| Activity of pemetrexed in pre-clinical chordoma models and humans. | Scientific reports | 2023 | 4 |
| Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. | BMC medicine | 2022 | 13 |
| Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. | British journal of cancer | 2022 | 11 |
| Dawn-to-dusk dry fasting induces anti-atherosclerotic, anti-inflammatory, and anti-tumorigenic proteome in peripheral blood mononuclear cells in subjects with metabolic syndrome. | Metabolism open | 2022 | 7 |
Showing 5 of 63 papers.
Protein variant mentions (28)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A302V | 1 | 2010 | PMID 20074521 |
| p.E205K | 1 | 2015 | PMID 25741868 |
| p.E287X | 1 | 2016 | PMID 27123046 |
| p.E288A | 1 | 2015 | PMID 25741868 |
| p.E288K | 1 | 2015 | PMID 25741868 |
Showing 5 of 28 variants.
Literature-extracted relations (48)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| (nab)-paclitaxel | Chemical | associate |
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. | 2012 |
| Vinorelbine | Chemical | associate |
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. | 2012 |
| Malformations of Cortical Development | Disease | associate |
Novel variants in TUBA1A cause congenital fibrosis of the extraocular muscles with or without malformations of cortical brain development. | 2021 |
| Lymphoma, T-Cell, Peripheral | Disease | associate |
Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) <i>versus</i> CHOP in newly diagnosed peripheral T-cell lymphoma patients. | 2020 |
| Intellectual Disability | Disease | associate |
Altered White Matter Organization in the TUBB3 E410K Syndrome. | 2019 |
Showing 5 of 48 relation assertions.
Organizations publishing (95)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Boston Children's Hospital | Hospital | 9 | 2010 to 2021 |
| Government of the United States of America | Government | 6 | 2017 to 2021 |
| Harvard Medical School | Academic | 4 | 2014 to 2021 |
| Harris Health System | Hospital | 3 | 2014 to 2022 |
| Mass General Brigham | Hospital | 2 | 2015 to 2018 |
Showing 5 of 95 organizations.
Where TUBB3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
350 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, trial mentions, and human sample screening reference.